← COLLEGIUM PHARMACEUTICAL, INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($94.2m) | ($74.9m) | ($39.1m) | ($22.7m) | $26.8m | $71.5m | ($25.0m) | $48.2m | $69.2m | $62.9m | — | |
| Depreciation, Depletion and Amortization | $655k | $594k | $1.1m | $731k | $870k | $1.7m | $2.7m | $3.5m | $3.9m | $4.2m | $233.6m | |
| Depreciation | $258k | $336k | $1.1m | $731k | $870k | $1.7m | $2.7m | $3.5m | $3.9m | $4.2m | $4.2m | |
| Amortization of Debt Issuance Costs and Discounts | — | — | — | — | $9.0m | $3.4m | $8.3m | $8.6m | $6.0m | $5.3m | — | |
| Amortization of Intangible Assets | $397k | — | $109.8m | $14.8m | $60.7m | $67.2m | — | — | — | $221.9m | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | ($78.0m) | ($8.4m) | ($2.2m) | ($26.8m) | ($25.7m) | ($30.3m) | |
| Share-based Payment Arrangement, Noncash Expense | $5.8m | $7.9m | $13.8m | $16.5m | $21.9m | $24.3m | $22.9m | $27.1m | $32.4m | $41.9m | $44.9m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | $68k | $560k | $822k | $2.3m | $4.1m | $4.0m | $8.4m | $19.2m | $12.8m | — | |
| Share-based Payment Arrangement, Expense | $5.8m | $7.9m | $13.8m | $16.5m | $21.9m | $24.3m | $22.9m | $27.1m | $32.4m | — | $44.9m | |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | — | $1.8m | — | — | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | ($94k) | $582k | — | — | — | — | — | — | — | — | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | ($2.1m) | $7.8m | $68.2m | ($5.0m) | $10.4m | $22.5m | $21.8m | ($3.6m) | $4.4m | ($17.2m) | ($13.6m) | |
| Increase (Decrease) in Inventories | ($1.3m) | $497k | ($219k) | $1.8m | $8.3m | $2.3m | ($48.3m) | ($14.2m) | ($13.9m) | $5.4m | ($5.2m) | |
| Increase (Decrease) in Accounts Payable | $5.6m | ($3.4m) | $6.5m | ($5.9m) | $3.8m | ($5.8m) | ($707k) | $5.1m | ($11.3m) | $6.7m | ($3.7m) | |
| Net Cash Provided by (Used in) Operating Activities | ($75.1m) |
($67.0m)
+10.71%
|
$169.4m
+352.75%
|
$27.8m
-83.60%
|
$93.9m
+238.13%
|
$103.6m
+10.24%
|
$124.2m
+19.96%
|
$274.7m
+121.16%
|
$205.0m
-25.39%
|
$329.3m
+60.66%
|
$329.9m
+0.18%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $477k | $990k | $5.5m | $6.4m | $5.5m | $1.9m | $1.6m | $461k | $1.7m | $1.7m | ($1.6m) | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | — | — | — | — | $572.1m | — | — | $0 | ($655.4m) | |
| Net Cash Provided by (Used in) Investing Activities | ($3.0m) | ($990k) | ($24.4m) | ($6.4m) | ($373.8m) | ($1.9m) | ($573.7m) | ($70.8m) | ($287.8m) | ($63.5m) | ($551.9m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | — | $2.7m | — | — | $11.5m | — | — | — | — | — | ($617.8m) | |
| Gain (Loss) on Extinguishment of Debt | — | — | — | — | — | — | — | ($23.5m) | ($11.3m) | ($16.0m) | — | |
| Proceeds from Issuance of Long-term Debt | — | — | $10.0m | — | — | — | — | $0 | $0 | — | $864.7m | |
| Payments for Repurchase of Common Stock | — | — | — | — | — | $47.9m | $14.1m | $75.0m | $60.0m | $25.1m | — | |
| Proceeds from Issuance of Common Stock | $137.3m | $34.3m | ($30k) | $817k | $758k | $755k | $337k | $460k | $827k | $1.4m | — | |
| Net Cash Provided by (Used in) Financing Activities | $135.6m |
$33.5m
-75.30%
|
($117.2m)
-450.05%
|
$2.0m
+101.74%
|
$286.5m
+13935.96%
|
($89.3m)
-131.17%
|
$436.7m
+589.04%
|
($140.2m)
-132.10%
|
($60.6m)
+56.77%
|
($110.2m)
-81.91%
|
$234.1m
+312.35%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $57.5m | ($34.5m) | $146.6m | $170.0m | $176.7m | $189.0m | $176.2m | $240.0m | $96.6m | $252.2m | $150.4m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $443k | $736k | $4.3m | $2.0m | $6.6m | $12.0m | $11.8m | $8.6m | $10.2m | $4.3m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $284k | $139k | $582k | $709k | $19.0m | $17.6m | $52.5m | $73.3m | $62.4m | $68.8m | — | |
| Income Taxes Paid, Net | — | — | — | — | $483k | $3.0m | $10.4m | $24.2m | $52.1m | $60.0m | — | |
| Additional Financial Items | ||||||||||||
| Goodwill | — | — | — | — | — | — | $133.7m | $133.9m | $162.3m | $145.9m | — | |
| Income Tax Expense (Benefit) | — | — | — | — | $830k | ($74.9m) | ($3.8m) | $27.6m | $29.4m | $29.7m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $74.0m | $82.3m | — | |
| Operating Expenses | $95.8m | — | — | — | $123.6m | $133.0m | $176.2m | $159.2m | $207.4m | $283.6m | — | |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | $280.4m | — | — | — | — | — | — | — | — |